This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (7) Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Parellada, E. Articles by Gaebel, W. Search for Related Content PubMed PubMed Citation Articles by Parellada, E. Articles by Gaebel, W. Social Bookmarking                         What's this?

Patients in the early phases of schizophrenia and schizoaffective disorders effectively treated with risperidone long-acting injectable

Hospital Clinic de Barcelona, Barcelona, Spain, eparella{at}clinic.ub.es

R. Andrezina

Mental Health Care Centre, Riga, Latvia

V. Milanova

Clinic of Women’s Psychiatry, Alexandrovska Hospital 1, Sofia, Bulgaria

P. Glue

Distrikspyskiatrisk Team, Vestfyn, Middelfart, Denmark

M. Masiak

Department of Psychiatry, Medical University of Lublin, Lublin, Poland

M. St. John Turner

The Larkfield Centre, Glasgow, UK

R. Medori

Janssen-Cilag, Medical Affairs, EMEA, Beerse, Belgium

W. Gaebel

Department of Psychiatry, Heinrich-Heine-Universität Düsseldorf, Duesseldorf, Germany

The efficacy and safety of risperidone long-acting injectable (RLAI) was investigated in patients in the early phases of schizophrenia and schizoaffective disorders ( 3 years).

Patients who required a treatment change received RLAI (2-weekly gluteal injections of 25, 37.5 or 50mg, per clinical judgement), without an oral risperidone run-in phase.

A total of 382 patients were included in this 6-month open-label study; 73% of patients completed the study. A total of 84% had schizophrenia with a median duration of 1.0 year since diagnosis. Previous medications were mainly atypical antipsychotics (70%) and depot neuroleptics (24%). The main reasons for treatment change were non-compliance (42%) and insufficient efficacy (31%) of previous medication. The total Positive and Negative Syndrome Scale (PANSS) and all its subscale scores improved significantly (p 0.0001), with 40% of patients showing a 20% improvement on total PANSS. Global Assessment of Functioning, quality of life, patient satisfaction and movement disorders also improved significantly. Tolerability of RLAI was generally good and no unexpected adverse events were reported.

The ensured delivery of medication with RLAI resulted in significant symptom improvement in this patient population. Direct initiation of RLAI is well accepted by patients. RLAI might represent a novel option for patients in the early phases of psychosis.

Key Words: risperidone long-acting injectable • schizophrenia • PANSS • tolerability

Journal of Psychopharmacology, Vol. 19, No. 5 suppl, 5-14 (2005)
DOI: 10.1177/0269881105056513


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				J. C. West, S. C. Marcus, J. Wilk, L. M. Countis, D. A. Regier, and M. Olfson Use of Depot Antipsychotic Medications for Medication Nonadherence in Schizophrenia Schizophr Bull, September 1, 2008; 34(5): 995 - 1001. [Abstract] [Full Text] [PDF]

				P. Chue The relationship between patient satisfaction and treatment outcomes in schizophrenia J Psychopharmacol, November 1, 2006; 20(6_suppl): 38 - 56. [Abstract] [PDF]